Constellation Pharmaceuticals, Inc. (CNST)
(Delayed Data from NSDQ)
$13.30 USD
+0.45 (3.50%)
Updated May 3, 2019 04:00 PM ET
After-Market: $13.15 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$13.30 USD
+0.45 (3.50%)
Updated May 3, 2019 04:00 PM ET
After-Market: $13.15 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Constellation (CNST) Surges on Takeover Deal With MorphoSys
by Zacks Equity Research
Constellation (CNST) skyrockets following the acquisition deal with German biotech company, MorphoSys, worth $1.7 billion.
Why Constellation Pharmaceuticals (CNST) Might Surprise This Earnings Season?
by Zacks Equity Research
Constellation Pharmaceuticals (CNST) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Constellation Pharmaceuticals, Inc. (CNST) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Constellation Pharmaceuticals, Inc. (CNST) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Is Constellation (CNST) Stock a Solid Choice Right Now?
by Zacks Equity Research
Constellation (CNST) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
What Makes Constellation Pharmaceuticals, Inc. (CNST) a New Buy Stock
by Zacks Equity Research
Constellation Pharmaceuticals, Inc. (CNST) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Why You Shouldn't Bet Against Constellation Pharmaceuticals (CNST) Stock
by Zacks Equity Research
Constellation Pharmaceuticals (CNST) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well
What Makes Constellation Pharmaceuticals, Inc. (CNST) a New Buy Stock
by Zacks Equity Research
Constellation Pharmaceuticals, Inc. (CNST) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Biotech Rally Sends Nasdaq to 9000: ETFs in Focus
by Sanghamitra Saha
Some biotech stocks have contributed materially to the Nasdaq's 1000-point gain since Aug 27, 2018 and helped it notch a record 9,000 on Dec 26.
Biotech Tops in November: Best ETFs & Stocks
by Sweta Killa
The biotech space of the broad healthcare sector outperformed others in November, courtesy of a series of positive news including study results, regulatory backdrop and deal activities.
Here's Why Momentum Investors Will Love Constellation Pharmaceuticals, Inc. (CNST)
by Zacks Equity Research
Does Constellation Pharmaceuticals, Inc. (CNST) have what it takes to be a top stock pick for momentum investors? Let's find out.
Will Constellation Pharmaceuticals Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Constellation Pharmaceuticals.
Constellation Pharmaceuticals (CNST) Looks Good: Stock Adds 8.3% in Session
by Zacks Equity Research
Constellation Pharmaceuticals (CNST) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
What's in Store for Universal Health (UHS) Q4 Earnings?
by Zacks Equity Research
Universal Health's (UHS) earnings in the fourth quarter are likely to gain from higher admissions and patient days.
Molina Healthcare (MOH) Q4 Earnings & Revenues Top Estimates
by Zacks Equity Research
Molina Healthcare's (MOH) fourth-quarter earnings trump estimates on the back of lower costs and higher premium revenues.
Ensign Group's (ENSG) Q4 Earnings Top Estimates, Surge Y/Y
by Zacks Equity Research
Ensign Group's (ENSG) fourth-quarter earnings rise on the back of solid segmental growth.
MEDNAX (MD) Q4 Earnings Surpass Estimates, Increase Y/Y
by Zacks Equity Research
Mednax's (MD) Q4 gains on revenue growth. However, the same is partly offset by rise in expenses.
Can Higher Revenues Buoy T-Mobile's (TMUS) Q4 Earnings?
by Zacks Equity Research
For the fourth quarter, T-Mobile (TMUS) is likely to report higher year-over-year revenues driven by customer growth on the back of coverage expansion and network performance.
Will Revenue Growth Support GoPro's (GPRO) Q4 Earnings?
by Zacks Equity Research
For the fourth quarter, GoPro (GPRO) is likely to report higher year-over-year revenues driven by increasing market traction of HERO7 Black.